ReviewCurrent opinion in oncology2016
Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.
Review in Current opinion in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model.NPJ systems biology and applications · 2024Article
- Diagnostic value of two-time point [Scientific reports · 2023Article
- Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging.World journal of clinical oncology · 2021Review
- Optimized Application ofFrontiers in medicine · 2021Article
- Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.Molecules (Basel, Switzerland) · 2020Article
- (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.Theranostics · 2020Article
- Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.World journal of urology · 2019Article
- Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.Molecular imaging and biology · 2019Article
- Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.Clinical nuclear medicine · 2019Article
- The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study.American journal of nuclear medicine and molecular imaging · 2019Article
- Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases.Frontiers in oncology · 2019Article
- MRI-Derived Radiomics to Guide Post-operative Management for High-Risk Prostate Cancer.Frontiers in oncology · 2019Article
- Advances in prostate-specific membrane antigen PET of prostate cancer.Current opinion in oncology · 2018Review
- Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.American journal of nuclear medicine and molecular imaging · 2018Review
- PET imaging of recurrent and metastatic prostate cancer with novel tracers.Future oncology (London, England) · 2016Review
- PSMA PET and Radionuclide Therapy in Prostate Cancer.Seminars in nuclear medicine · 2016Review
- Unusual presentation of castrate-resistant prostate cancer with urethral and inguinal nodal metastasis.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
- Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer.World journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewIncreasing attention is being given to personalized medicine in oncology, where therapies are tailored to the particular characteristics of the individual cancer patient. In recent years, there has been greater focus on prostate-specific membrane antigen (PSMA) in prostate cancer (PCa) as a target for imaging and therapy with radionuclides. This review highlights the recent advancements in PSMA positron emission tomography (PET) in PCa during the past year. RECENT
findingsSeveral reports on PSMA PET/computed tomography (CT) in PCa patients are demonstrating promising results, especially for detection of biochemical recurrence. F-PSMA PET/CT may be superior to Ga-PSMA PET/CT. The detection rate of PSMA PET is influenced by prostate-specific antigen level. PSMA PET/CT may have a higher detection rate than choline PET/CT. Only a few reports have been published on PSMA PET/magnetic resonance imaging (MRI), and this modality remains to be elucidated further. SUMMARY: Molecular imaging with PSMA PET is paving the way for personalized medicine in PCa. However, large prospective clinical studies are needed to further evaluate the role of PSMA PET/CT and PET/MRI in the clinical workflow of PCa. PSMA is an excellent target for imaging and therapy with radionuclides, and the 'image and treat' strategy has the potential to become a milestone in the management of PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.